ada standards of care 2025 obesity pharmacotherapy glp-1 for management in adults: clinical practice guideline update 2025 Concise Clinical Guidance: An

Conclusions GLP-1RA use was not associated with a decreased or increased risk of AF compared to DPP4i use

Get affordable online weight loss management with experienced doctors

Online health and wellness company Hims & Hers posted a $92 million loss in the first quarter as it shifts its business from selling compounded weight loss drugs to branded GLP-1 medications.

However

The Risks: Unknown ingredients and contamination Incorrect dosages and life-threatening side effects No regulatory oversight or safety data Why This Is Critical: Patients are bypassing pharmacies and getting injections from sketchy online vendors This undermines real GLP1 therapies and can lead to serious harm As healthcare professionals, we must: Ask patients about the source of their medications Report adverse reactions to MedWatch Educate our patients about safe access and real prescriptions Lets advocate for ethical prescribing and responsible patient care in the GLP1 era

ANZCA and peak diabetes, obesity and gastroenterological bodies have produced an updated set of clinical practice recommendations for patients using GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists